Teva-Kowa Faces Uphill Battle With Japanese Domestic And Foreign Generic Drug Makers
This article was originally published in PharmAsia News
Executive Summary
Beginning in April, a new joint venture between generic firm Teva and Kowa, a mid-sized Japanese drug maker, will make its official debut in Japan. Aiming to generate ¥100 billion in sales by 2015 and thus becoming the leading generic drug maker in Japan, Teva-Kowa Pharma could drastically change the fast-growing - and yet still lagging - Japanese generic drug market
You may also be interested in...
Teva Buys Japanese Generics Company For $460 Mil.
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company
Teva Buys Japanese Generics Company For $460 Mil.
Teva Pharmaceutical Industries Ltd. announced May 16 that it is acquiring more than half of Japan's third largest generic drugmaker and extending an offer to purchase the remaining portion of the company
Teva Buys Majority Stake In Japanese Generics Company For $460 Mil.
The world's largest maker of generic drugs buys access to the rapidly growing Japanese generics market with the acquisition of Taiyo Pharmaceuticals.